Skip to content

Ketamine: all studies

Page 207 of 449: studies 2,061 to 2,070 of 4,483, newest first. Back to the ketamine overview

Research

Increasing Prevalence of Ketamine in Drivers in New York City Including the Identification of 2-Fluoro-Deschloroketamine.

Journal of Analytical Toxicology September 17, 2021 Elba Arango, Allison Toriello, Zoila Rosario et al. 17 citations

Ketamine is a dissociative anesthetic used in veterinary and human medicine since the 1970s. Its clinical use has expanded to control of seizures, by pre-hospital emergency medical services (EMS), and is finding new purpose as an analgesic alternative and antidepressant. Ketamine brings hope for effective management of chronic pain in the absence of opioids and decreasing suicidal ideations;...

Neuroprotective effects of curcumin-loaded nanophytosome on ketamine-induced schizophrenia-like behaviors and oxidative damage in male mice.

Neuroscience Letters September 15, 2021 A. Hajizadeh Moghaddam, Khadijeh Maboudi, Bita Bavaghar et al.

Curcumin as an antioxidant natural herb has shown numerous pharmacological effects. However, the poor bioavailability of curcumin is a significant pharmacological barrier for its antioxidant activities. The present study was conducted to develop curcumin-loaded nanophytosome (CNP) and explore their therapeutic potential in a ketamine (KET)-induced schizophrenia (SCZ) model. The mice in our...

Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine

Journal of Neuroinflammation September 15, 2021 Yanling Zhou, Chengyu Wang, Xiaofeng Lan et al. 61 citations

Treatment-resistant depression (TRD) and pain frequently coexist clinically. Ketamine has analgesic and antidepressant effects, but few studies have evaluated individual differences in antidepressant outcomes to repeated ketamine in TRD patients with comorbid pain. Our aims were to determine the difference in ketamine’s antidepressant effects in TRD patients with or without pain and then to...

Ketamine ameliorates depressive-like behaviors in mice through increasing glucose uptake regulated by the ERK/GLUT3 signaling pathway

Scientific Reports September 13, 2021 Xin-ping Ouyang, Zhengjia Wang, Mei Luo et al.

To investigate the effects of ketamine on glucose uptake and glucose transporter (GLUT) expression in depressive-like mice. After HA1800 cells were treated with ketamine, 2-[N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino]-2-Deoxyglucose (2-NBDG) was added to the cells to test the effects of ketamine on glucose uptake, production of lactate, and expression levels of GLUT, ERK1/2, AKT, and AMPK....

Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.

Cochrane Database of Systematic Reviews September 12, 2021 Rebecca L. Dean, Claudia C. Hurducas, Keith Hawton et al. 97 citations

BACKGROUND Many studies have recently been conducted to assess the antidepressant efficacy of glutamate modification in mood disorders. This is an update of a review first published in 2015 focusing on the use of glutamate receptor modulators in unipolar depression. OBJECTIVES To assess the effects - and review the acceptability and tolerability - of ketamine and other glutamate receptor...

Ketamine: Neuroprotective or Neurotoxic?

Frontiers in Neuroscience September 10, 2021 Divya Choudhury, Anita E. Autry, K. Tolias et al. 75 citations

Ketamine, a non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist, has been employed clinically as an intravenous anesthetic since the 1970s. More recently, ketamine has received attention for its rapid antidepressant effects and is actively being explored as a treatment for a wide range of neuropsychiatric syndromes. In model systems, ketamine appears to display a combination of...

miR-98-5p plays a critical role in depression and antidepressant effect of ketamine

Translational Psychiatry September 3, 2021 Chao Huang, Yuanyuan Wang, Zifeng Wu et al. 29 citations

Ketamine has been demonstrated to be a rapid-onset and long-lasting antidepressant, but its underlying molecular mechanisms remain unclear. Recent studies have emerged microRNAs as important modulators for depression treatment. In this study, we report that miR-98-5p is downregulated in the prefrontal cortex and hippocampus of mice subjected to chronic social stress, while overexpressing it by...

KETAMINE THERAPY COMBINED WITH REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (rTMS) FOR MAJOR DEPRESSIVE DISORDER AT A SUBURBAN TERTIARY CLINIC

Brain Stimulation September 1, 2021 M. Davila, A. Hess, Ananya Louviere et al.

Background: Repetitive transcranial magnetic stimulation (rTMS) is a neurostimulatory technique approved for the treatment of major https://doi.org/10.1016/j.brs.2021.07.023 depressive disorder (MDD) impacting orbital frontal cortex functioning. We have previously identified significant changes in ratings for several standard metrics for depression, anxiety, pain and ADHD after 6 weeks of...

Ketamine-Assisted and Culturally Attuned Trauma Informed Psychotherapy as Adjunct to Traditional Indigenous Healing: Effecting Cultural Collaboration in Canadian Mental Health Care.

Behavioral Sciences August 31, 2021 Sherry-Anne Muscat, Geralyn Dorothy Wright, Kristy Bergeron et al. 5 citations

Ketamine therapy with culturally attuned trauma-informed psychotherapy in a collaborative cross-cultural partnership may provide a critical step in the operationalization and optimization of treatment effectiveness in diverse populations and may provide a foundation for an improved quality of life for Indigenous people. Decolonizing Indigenous health and wellbeing is long overdue, requiring an...

Low Doses of Ketamine and Melatonin in Combination Produce Additive Antidepressant-like Effects in Mice

International Journal of Molecular Sciences August 26, 2021 Rosa Estrada-Reyes, Daniel B Quero-Chávez, Citlali Trueta et al.

Major depressive disorder is a disabling disease with the number of affected individuals increasing each year. Current antidepressant treatments take between three to six weeks to be effective with forty percent of patients being resistant to treatment, making it necessary to search for new antidepressant treatments. Ketamine, a phencyclidine hydrochloride derivative, given intravenously,...